
Smokers with diabetes or obesity who take semaglutide (Ozempic/Wegovy) might reap an added benefit: Help in quitting smoking. A yearlong study found that, compared to people using other diabetes drugs, fewer patients who were taking semaglutide sought out medical help to quit smoking. That suggests the drug might have already been helping them to quit, researchers noted. The finding wasn’t a complete surprise to researchers at the National Institute on Drug Abuse (NIDA), since “clinical anecdotes that patients treated with semaglutide … [have] reported reduced desire to smoke” have already been widespread, they said. The new study was published July 29 in the Annals of Internal Medicine. How might semaglutide cut down on smoking? The researchers noted these drugs (along with Mounjaro and Zepbound) are glucagon-like peptide receptor agonists (GLP-1s), which work to suppress appetite by targeting specific receptors in the brain. Studies in mice have shown that GLP-1s also reduce “nicotine-induced increases in dopamine release” in a specific brain area, “a common mechanism underlying the rewarding effects of addictive drugs,” the researchers explained. The new study was led by NIDA director Dr. Nora Volkow. Her team analyzed data from seven trials, all involving smokers who also had type 2 diabetes. Almost 223,000 patients were tracked for a year, and they took a variety of diabetes meds, including insulin, metformin and sulfonylureas, among others. A… read on > read on >